Changchun Hi-Tech announced that the company previously disclosed that Jinsai Pharmaceutical obtained rights related to leuprorelin mesylate injections. Recently, Jinsai Pharmaceutical received the “Drug Registration Certificate” approved and issued by the State Drug Administration. The application for registration and marketing license for drugs produced overseas was approved. The approved indication is prostate cancer requiring androgen castration treatment. The specification is 42 mg, and the drug approval number is Sinopharm's license HJ20260087.

Zhitongcaijing · 3d ago
Changchun Hi-Tech announced that the company previously disclosed that Jinsai Pharmaceutical obtained rights related to leuprorelin mesylate injections. Recently, Jinsai Pharmaceutical received the “Drug Registration Certificate” approved and issued by the State Drug Administration. The application for registration and marketing license for drugs produced overseas was approved. The approved indication is prostate cancer requiring androgen castration treatment. The specification is 42 mg, and the drug approval number is Sinopharm's license HJ20260087.